Temporal Characteristics of CSF-Venous Fistulas on Digital Subtraction Myelography.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
04 2023
Historique:
received: 15 11 2022
accepted: 06 02 2023
pmc-release: 01 04 2024
medline: 12 4 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

CSF-venous fistula can be diagnosed with multiple myelographic techniques; however, no prior work has characterized the time to contrast opacification and the duration of visualization. The purpose of our study was to evaluate the temporal characteristics of CSF-venous fistula on digital subtraction myelography. We reviewed the digital subtraction myelography images of 26 patients with CSF-venous fistulas. We evaluated how long the CSF-venous fistula took to opacify after contrast reached the spinal level of interest and how long it remained opacified. Patient demographics, CSF-venous fistula treatment, brain MR imaging findings, CSF-venous fistula spinal level, and CSF-venous fistula laterality were recorded. Eight of the 26 CSF-venous fistulas were seen on both the upper- and lower-FOV digital subtraction myelography, for a total of 34 CSF-venous fistula views evaluated on digital subtraction myelography. The mean time to appearance was 9.1 seconds (range, 0-30 seconds). Twenty-two (84.6%) of the CSF-venous fistulas were on the right. The highest fistula level was C7, while the lowest was T13 (13 rib-bearing vertebral bodies). The most common CSF-venous fistula levels were T6 (4 patients) followed by T8, T10, and T11 (3 patients each). The mean age was 58.3 years (range, 31.7-87.6 years). Sixteen patients were women (61.5%). This is the first study to report the temporal characteristics of CSF-venous fistulas using digital subtraction myelography. We found that on average, the CSF-venous fistula appeared 9.1 seconds (range, 0-30 seconds) after intrathecal contrast reached the spinal level.

Sections du résumé

BACKGROUND AND PURPOSE
CSF-venous fistula can be diagnosed with multiple myelographic techniques; however, no prior work has characterized the time to contrast opacification and the duration of visualization. The purpose of our study was to evaluate the temporal characteristics of CSF-venous fistula on digital subtraction myelography.
MATERIALS AND METHODS
We reviewed the digital subtraction myelography images of 26 patients with CSF-venous fistulas. We evaluated how long the CSF-venous fistula took to opacify after contrast reached the spinal level of interest and how long it remained opacified. Patient demographics, CSF-venous fistula treatment, brain MR imaging findings, CSF-venous fistula spinal level, and CSF-venous fistula laterality were recorded.
RESULTS
Eight of the 26 CSF-venous fistulas were seen on both the upper- and lower-FOV digital subtraction myelography, for a total of 34 CSF-venous fistula views evaluated on digital subtraction myelography. The mean time to appearance was 9.1 seconds (range, 0-30 seconds). Twenty-two (84.6%) of the CSF-venous fistulas were on the right. The highest fistula level was C7, while the lowest was T13 (13 rib-bearing vertebral bodies). The most common CSF-venous fistula levels were T6 (4 patients) followed by T8, T10, and T11 (3 patients each). The mean age was 58.3 years (range, 31.7-87.6 years). Sixteen patients were women (61.5%).
CONCLUSIONS
This is the first study to report the temporal characteristics of CSF-venous fistulas using digital subtraction myelography. We found that on average, the CSF-venous fistula appeared 9.1 seconds (range, 0-30 seconds) after intrathecal contrast reached the spinal level.

Identifiants

pubmed: 36894299
pii: ajnr.A7809
doi: 10.3174/ajnr.A7809
pmc: PMC10084909
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

492-495

Informations de copyright

© 2023 by American Journal of Neuroradiology.

Références

JAMA Neurol. 2019 May 1;76(5):580-587
pubmed: 30776059
AJNR Am J Neuroradiol. 2021 Jan;42(1):32-36
pubmed: 33122215
AJR Am J Roentgenol. 2022 Aug;219(2):292-301
pubmed: 35261281
J Neurosurg Spine. 2016 Jun;24(6):960-4
pubmed: 26849709
Clin Neuroradiol. 2022 Jun;32(2):537-545
pubmed: 34292360
AJNR Am J Neuroradiol. 2003 Sep;24(8):1711-4
pubmed: 13679297
AJNR Am J Neuroradiol. 2020 May;41(5):938-940
pubmed: 32354709
Neuroimaging Clin N Am. 2019 Nov;29(4):581-594
pubmed: 31677732
AJNR Am J Neuroradiol. 2022 Oct;43(10):1544-1547
pubmed: 36137659
Neurology. 2014 Jul 29;83(5):472-3
pubmed: 24951475
AJNR Am J Neuroradiol. 2020 Jan;41(1):21-28
pubmed: 31857327
Neurology. 2016 Aug 16;87(7):673-9
pubmed: 27440149
AJNR Am J Neuroradiol. 2020 Sep;41(9):1754-1756
pubmed: 32675336
Magn Reson Imaging. 2010 Nov;28(9):1306-10
pubmed: 20685054
J Neurosurg Spine. 2019 Sep 13;:1-4
pubmed: 31518974
Diagn Interv Radiol. 2018 Jan-Feb;24(1):54-59
pubmed: 29217497
J Neurosurg Spine. 2015 Mar;22(3):324-31
pubmed: 25555057
AJNR Am J Neuroradiol. 2021 May;42(5):986-992
pubmed: 33602750

Auteurs

I Mark (I)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.) Mark.Ian@mayo.edu.

A Madhavan (A)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.).

M Oien (M)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.).

J Verdoorn (J)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.).

J C Benson (JC)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.).

J Cutsforth-Gregory (J)

Neurology (J.C.-G.), Mayo Clinic, Rochester, Minnesota.

W Brinjikji (W)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.).

P Morris (P)

From the Departments of Radiology (I.M., A.M., M.O., J.V., J.C.B., W.B., P.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH